nodes	percent_of_prediction	percent_of_DWPC	metapath
Pseudoephedrine—IL2—epithelium—uterine cancer	0.0185	0.0799	CbGeAlD
Pseudoephedrine—IL2—uterine cervix—uterine cancer	0.0183	0.0792	CbGeAlD
Pseudoephedrine—IL2—renal system—uterine cancer	0.0171	0.0741	CbGeAlD
Pseudoephedrine—IL2—uterus—uterine cancer	0.0153	0.066	CbGeAlD
Pseudoephedrine—IL2—female reproductive system—uterine cancer	0.0137	0.0594	CbGeAlD
Pseudoephedrine—NFATC1—female gonad—uterine cancer	0.0137	0.0591	CbGeAlD
Pseudoephedrine—TNF—vagina—uterine cancer	0.013	0.056	CbGeAlD
Pseudoephedrine—IL2—female gonad—uterine cancer	0.0125	0.054	CbGeAlD
Pseudoephedrine—Cerebral haemorrhage—Medroxyprogesterone Acetate—uterine cancer	0.0106	0.0398	CcSEcCtD
Pseudoephedrine—NFATC1—lymph node—uterine cancer	0.00878	0.038	CbGeAlD
Pseudoephedrine—Paranoia—Medroxyprogesterone Acetate—uterine cancer	0.00863	0.0324	CcSEcCtD
Pseudoephedrine—TNF—lymph node—uterine cancer	0.00838	0.0362	CbGeAlD
Pseudoephedrine—IL2—lymph node—uterine cancer	0.00803	0.0347	CbGeAlD
Pseudoephedrine—Blood pressure increased—Progesterone—uterine cancer	0.00649	0.0243	CcSEcCtD
Pseudoephedrine—Blood pressure increased—Medroxyprogesterone Acetate—uterine cancer	0.00589	0.0221	CcSEcCtD
Pseudoephedrine—Lightheadedness—Progesterone—uterine cancer	0.00581	0.0218	CcSEcCtD
Pseudoephedrine—Euphoric mood—Medroxyprogesterone Acetate—uterine cancer	0.00506	0.0189	CcSEcCtD
Pseudoephedrine—MAOA—myometrium—uterine cancer	0.00462	0.02	CbGeAlD
Pseudoephedrine—Irritability—Progesterone—uterine cancer	0.0045	0.0169	CcSEcCtD
Pseudoephedrine—Psychotic disorder—Medroxyprogesterone Acetate—uterine cancer	0.00417	0.0156	CcSEcCtD
Pseudoephedrine—Irritability—Medroxyprogesterone Acetate—uterine cancer	0.00408	0.0153	CcSEcCtD
Pseudoephedrine—Urinary retention—Medroxyprogesterone Acetate—uterine cancer	0.00406	0.0152	CcSEcCtD
Pseudoephedrine—Angina pectoris—Progesterone—uterine cancer	0.00397	0.0149	CcSEcCtD
Pseudoephedrine—Dysuria—Progesterone—uterine cancer	0.00381	0.0143	CcSEcCtD
Pseudoephedrine—Pain—Carboplatin—uterine cancer	0.00377	0.0141	CcSEcCtD
Pseudoephedrine—SLC6A2—decidua—uterine cancer	0.00372	0.0161	CbGeAlD
Pseudoephedrine—ADRA1A—epithelium—uterine cancer	0.00366	0.0158	CbGeAlD
Pseudoephedrine—MAOA—uterine cervix—uterine cancer	0.0036	0.0156	CbGeAlD
Pseudoephedrine—ADRA2A—myometrium—uterine cancer	0.00355	0.0153	CbGeAlD
Pseudoephedrine—Body temperature increased—Carboplatin—uterine cancer	0.00349	0.0131	CcSEcCtD
Pseudoephedrine—Dysuria—Medroxyprogesterone Acetate—uterine cancer	0.00345	0.0129	CcSEcCtD
Pseudoephedrine—ADRB1—female reproductive system—uterine cancer	0.00344	0.0149	CbGeAlD
Pseudoephedrine—MAOA—decidua—uterine cancer	0.00343	0.0148	CbGeAlD
Pseudoephedrine—ADRA1A—renal system—uterine cancer	0.0034	0.0147	CbGeAlD
Pseudoephedrine—MAOA—renal system—uterine cancer	0.00337	0.0146	CbGeAlD
Pseudoephedrine—SLC6A4—female reproductive system—uterine cancer	0.00332	0.0144	CbGeAlD
Pseudoephedrine—MAOA—endometrium—uterine cancer	0.00326	0.0141	CbGeAlD
Pseudoephedrine—Sweating—Medroxyprogesterone Acetate—uterine cancer	0.00316	0.0118	CcSEcCtD
Pseudoephedrine—MAOA—mammalian vulva—uterine cancer	0.00315	0.0136	CbGeAlD
Pseudoephedrine—Bradycardia—Medroxyprogesterone Acetate—uterine cancer	0.00301	0.0113	CcSEcCtD
Pseudoephedrine—MAOA—uterus—uterine cancer	0.003	0.013	CbGeAlD
Pseudoephedrine—SLC6A2—female reproductive system—uterine cancer	0.00293	0.0127	CbGeAlD
Pseudoephedrine—Tension—Progesterone—uterine cancer	0.00279	0.0104	CcSEcCtD
Pseudoephedrine—ADRA2A—uterine cervix—uterine cancer	0.00276	0.0119	CbGeAlD
Pseudoephedrine—Nervousness—Progesterone—uterine cancer	0.00276	0.0103	CcSEcCtD
Pseudoephedrine—Muscle spasms—Progesterone—uterine cancer	0.00273	0.0102	CcSEcCtD
Pseudoephedrine—MAOA—female reproductive system—uterine cancer	0.0027	0.0117	CbGeAlD
Pseudoephedrine—Tremor—Progesterone—uterine cancer	0.00266	0.00997	CcSEcCtD
Pseudoephedrine—ADRA2A—decidua—uterine cancer	0.00263	0.0114	CbGeAlD
Pseudoephedrine—Vertigo—Progesterone—uterine cancer	0.00255	0.00956	CcSEcCtD
Pseudoephedrine—Tension—Medroxyprogesterone Acetate—uterine cancer	0.00252	0.00946	CcSEcCtD
Pseudoephedrine—Palpitations—Progesterone—uterine cancer	0.00251	0.0094	CcSEcCtD
Pseudoephedrine—Nervousness—Medroxyprogesterone Acetate—uterine cancer	0.0025	0.00936	CcSEcCtD
Pseudoephedrine—ADRA2A—endometrium—uterine cancer	0.0025	0.0108	CbGeAlD
Pseudoephedrine—Muscle spasms—Medroxyprogesterone Acetate—uterine cancer	0.00247	0.00927	CcSEcCtD
Pseudoephedrine—MAOA—female gonad—uterine cancer	0.00245	0.0106	CbGeAlD
Pseudoephedrine—Hypertension—Progesterone—uterine cancer	0.00245	0.00919	CcSEcCtD
Pseudoephedrine—MAOA—vagina—uterine cancer	0.00244	0.0105	CbGeAlD
Pseudoephedrine—Chest pain—Progesterone—uterine cancer	0.00242	0.00906	CcSEcCtD
Pseudoephedrine—ADRA2A—mammalian vulva—uterine cancer	0.00242	0.0104	CbGeAlD
Pseudoephedrine—Tremor—Medroxyprogesterone Acetate—uterine cancer	0.00241	0.00903	CcSEcCtD
Pseudoephedrine—Anxiety—Progesterone—uterine cancer	0.00241	0.00903	CcSEcCtD
Pseudoephedrine—Agitation—Medroxyprogesterone Acetate—uterine cancer	0.00236	0.00886	CcSEcCtD
Pseudoephedrine—Confusional state—Progesterone—uterine cancer	0.00234	0.00876	CcSEcCtD
Pseudoephedrine—Vertigo—Medroxyprogesterone Acetate—uterine cancer	0.00231	0.00866	CcSEcCtD
Pseudoephedrine—ADRA2A—uterus—uterine cancer	0.0023	0.00995	CbGeAlD
Pseudoephedrine—Palpitations—Medroxyprogesterone Acetate—uterine cancer	0.00227	0.00852	CcSEcCtD
Pseudoephedrine—Tachycardia—Progesterone—uterine cancer	0.00226	0.00848	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Progesterone—uterine cancer	0.00224	0.00839	CcSEcCtD
Pseudoephedrine—Anorexia—Progesterone—uterine cancer	0.00221	0.00828	CcSEcCtD
Pseudoephedrine—Chest pain—Medroxyprogesterone Acetate—uterine cancer	0.00219	0.00821	CcSEcCtD
Pseudoephedrine—Anxiety—Medroxyprogesterone Acetate—uterine cancer	0.00218	0.00818	CcSEcCtD
Pseudoephedrine—Delirium—Epirubicin—uterine cancer	0.00217	0.00811	CcSEcCtD
Pseudoephedrine—Confusional state—Medroxyprogesterone Acetate—uterine cancer	0.00212	0.00793	CcSEcCtD
Pseudoephedrine—Insomnia—Progesterone—uterine cancer	0.0021	0.00785	CcSEcCtD
Pseudoephedrine—ADRA2A—female reproductive system—uterine cancer	0.00207	0.00894	CbGeAlD
Pseudoephedrine—Dyspnoea—Progesterone—uterine cancer	0.00207	0.00774	CcSEcCtD
Pseudoephedrine—Tachycardia—Medroxyprogesterone Acetate—uterine cancer	0.00205	0.00768	CcSEcCtD
Pseudoephedrine—Dyspepsia—Progesterone—uterine cancer	0.00204	0.00764	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Medroxyprogesterone Acetate—uterine cancer	0.00203	0.00761	CcSEcCtD
Pseudoephedrine—Decreased appetite—Progesterone—uterine cancer	0.00201	0.00755	CcSEcCtD
Pseudoephedrine—Delirium—Doxorubicin—uterine cancer	0.002	0.00751	CcSEcCtD
Pseudoephedrine—Anorexia—Medroxyprogesterone Acetate—uterine cancer	0.002	0.0075	CcSEcCtD
Pseudoephedrine—CYP2D6—renal system—uterine cancer	0.002	0.00865	CbGeAlD
Pseudoephedrine—Pain—Progesterone—uterine cancer	0.00198	0.00743	CcSEcCtD
Pseudoephedrine—Etomidate—CYP19A1—uterine cancer	0.00197	1	CrCbGaD
Pseudoephedrine—Feeling abnormal—Progesterone—uterine cancer	0.00191	0.00716	CcSEcCtD
Pseudoephedrine—Insomnia—Medroxyprogesterone Acetate—uterine cancer	0.0019	0.00712	CcSEcCtD
Pseudoephedrine—ADRA2A—female gonad—uterine cancer	0.00188	0.00814	CbGeAlD
Pseudoephedrine—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.00187	0.00702	CcSEcCtD
Pseudoephedrine—ADRA2A—vagina—uterine cancer	0.00187	0.00809	CbGeAlD
Pseudoephedrine—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.00185	0.00693	CcSEcCtD
Pseudoephedrine—Body temperature increased—Progesterone—uterine cancer	0.00183	0.00686	CcSEcCtD
Pseudoephedrine—Decreased appetite—Medroxyprogesterone Acetate—uterine cancer	0.00183	0.00684	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.00173	0.00648	CcSEcCtD
Pseudoephedrine—SLC6A2—lymph node—uterine cancer	0.00171	0.0074	CbGeAlD
Pseudoephedrine—Asthenia—Progesterone—uterine cancer	0.00166	0.00623	CcSEcCtD
Pseudoephedrine—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.00166	0.00622	CcSEcCtD
Pseudoephedrine—CYP2D6—female reproductive system—uterine cancer	0.0016	0.00693	CbGeAlD
Pseudoephedrine—MAOA—lymph node—uterine cancer	0.00158	0.00682	CbGeAlD
Pseudoephedrine—Anorexia—Dactinomycin—uterine cancer	0.00156	0.00585	CcSEcCtD
Pseudoephedrine—Dizziness—Progesterone—uterine cancer	0.00153	0.00574	CcSEcCtD
Pseudoephedrine—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.00151	0.00565	CcSEcCtD
Pseudoephedrine—Vomiting—Progesterone—uterine cancer	0.00147	0.00552	CcSEcCtD
Pseudoephedrine—Rash—Progesterone—uterine cancer	0.00146	0.00548	CcSEcCtD
Pseudoephedrine—Dermatitis—Progesterone—uterine cancer	0.00146	0.00547	CcSEcCtD
Pseudoephedrine—CYP2D6—female gonad—uterine cancer	0.00146	0.0063	CbGeAlD
Pseudoephedrine—Headache—Progesterone—uterine cancer	0.00145	0.00544	CcSEcCtD
Pseudoephedrine—Decreased appetite—Dactinomycin—uterine cancer	0.00142	0.00534	CcSEcCtD
Pseudoephedrine—Pain—Dactinomycin—uterine cancer	0.0014	0.00525	CcSEcCtD
Pseudoephedrine—Muscle spasms—Etoposide—uterine cancer	0.0014	0.00523	CcSEcCtD
Pseudoephedrine—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.00139	0.0052	CcSEcCtD
Pseudoephedrine—Nausea—Progesterone—uterine cancer	0.00138	0.00516	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Dactinomycin—uterine cancer	0.00135	0.00506	CcSEcCtD
Pseudoephedrine—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.00133	0.005	CcSEcCtD
Pseudoephedrine—Rash—Medroxyprogesterone Acetate—uterine cancer	0.00132	0.00496	CcSEcCtD
Pseudoephedrine—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.00132	0.00496	CcSEcCtD
Pseudoephedrine—Headache—Medroxyprogesterone Acetate—uterine cancer	0.00132	0.00493	CcSEcCtD
Pseudoephedrine—Vertigo—Etoposide—uterine cancer	0.0013	0.00489	CcSEcCtD
Pseudoephedrine—Body temperature increased—Dactinomycin—uterine cancer	0.00129	0.00485	CcSEcCtD
Pseudoephedrine—Hypertension—Etoposide—uterine cancer	0.00125	0.0047	CcSEcCtD
Pseudoephedrine—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.00125	0.00467	CcSEcCtD
Pseudoephedrine—Chest pain—Etoposide—uterine cancer	0.00124	0.00463	CcSEcCtD
Pseudoephedrine—ADRA2A—lymph node—uterine cancer	0.00121	0.00523	CbGeAlD
Pseudoephedrine—Confusional state—Etoposide—uterine cancer	0.0012	0.00448	CcSEcCtD
Pseudoephedrine—Asthenia—Dactinomycin—uterine cancer	0.00118	0.0044	CcSEcCtD
Pseudoephedrine—Tachycardia—Etoposide—uterine cancer	0.00116	0.00434	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Etoposide—uterine cancer	0.00115	0.00429	CcSEcCtD
Pseudoephedrine—Angina pectoris—Epirubicin—uterine cancer	0.00114	0.00427	CcSEcCtD
Pseudoephedrine—Anorexia—Etoposide—uterine cancer	0.00113	0.00423	CcSEcCtD
Pseudoephedrine—Dysuria—Epirubicin—uterine cancer	0.00109	0.00409	CcSEcCtD
Pseudoephedrine—Dyspnoea—Etoposide—uterine cancer	0.00106	0.00396	CcSEcCtD
Pseudoephedrine—Angina pectoris—Doxorubicin—uterine cancer	0.00105	0.00395	CcSEcCtD
Pseudoephedrine—Vomiting—Dactinomycin—uterine cancer	0.00104	0.0039	CcSEcCtD
Pseudoephedrine—Rash—Dactinomycin—uterine cancer	0.00103	0.00387	CcSEcCtD
Pseudoephedrine—Decreased appetite—Etoposide—uterine cancer	0.00103	0.00386	CcSEcCtD
Pseudoephedrine—Pain—Etoposide—uterine cancer	0.00101	0.0038	CcSEcCtD
Pseudoephedrine—Dysuria—Doxorubicin—uterine cancer	0.00101	0.00379	CcSEcCtD
Pseudoephedrine—Sweating—Epirubicin—uterine cancer	0.000999	0.00374	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Etoposide—uterine cancer	0.000977	0.00366	CcSEcCtD
Pseudoephedrine—Nausea—Dactinomycin—uterine cancer	0.000973	0.00365	CcSEcCtD
Pseudoephedrine—Bradycardia—Epirubicin—uterine cancer	0.000952	0.00357	CcSEcCtD
Pseudoephedrine—Body temperature increased—Etoposide—uterine cancer	0.000937	0.00351	CcSEcCtD
Pseudoephedrine—Sweating—Doxorubicin—uterine cancer	0.000924	0.00346	CcSEcCtD
Pseudoephedrine—Bradycardia—Doxorubicin—uterine cancer	0.000881	0.0033	CcSEcCtD
Pseudoephedrine—Asthenia—Etoposide—uterine cancer	0.00085	0.00319	CcSEcCtD
Pseudoephedrine—Arrhythmia—Epirubicin—uterine cancer	0.000835	0.00313	CcSEcCtD
Pseudoephedrine—Tension—Epirubicin—uterine cancer	0.000799	0.00299	CcSEcCtD
Pseudoephedrine—Nervousness—Epirubicin—uterine cancer	0.000791	0.00296	CcSEcCtD
Pseudoephedrine—Dizziness—Etoposide—uterine cancer	0.000784	0.00294	CcSEcCtD
Pseudoephedrine—Muscle spasms—Epirubicin—uterine cancer	0.000783	0.00293	CcSEcCtD
Pseudoephedrine—Arrhythmia—Doxorubicin—uterine cancer	0.000773	0.0029	CcSEcCtD
Pseudoephedrine—Vomiting—Etoposide—uterine cancer	0.000754	0.00282	CcSEcCtD
Pseudoephedrine—Agitation—Epirubicin—uterine cancer	0.000748	0.0028	CcSEcCtD
Pseudoephedrine—Rash—Etoposide—uterine cancer	0.000747	0.0028	CcSEcCtD
Pseudoephedrine—Dermatitis—Etoposide—uterine cancer	0.000747	0.0028	CcSEcCtD
Pseudoephedrine—Headache—Etoposide—uterine cancer	0.000743	0.00278	CcSEcCtD
Pseudoephedrine—Tension—Doxorubicin—uterine cancer	0.000739	0.00277	CcSEcCtD
Pseudoephedrine—Nervousness—Doxorubicin—uterine cancer	0.000732	0.00274	CcSEcCtD
Pseudoephedrine—Vertigo—Epirubicin—uterine cancer	0.000731	0.00274	CcSEcCtD
Pseudoephedrine—Muscle spasms—Doxorubicin—uterine cancer	0.000724	0.00271	CcSEcCtD
Pseudoephedrine—Palpitations—Epirubicin—uterine cancer	0.000719	0.0027	CcSEcCtD
Pseudoephedrine—Nausea—Etoposide—uterine cancer	0.000704	0.00264	CcSEcCtD
Pseudoephedrine—Hypertension—Epirubicin—uterine cancer	0.000703	0.00263	CcSEcCtD
Pseudoephedrine—Chest pain—Epirubicin—uterine cancer	0.000693	0.0026	CcSEcCtD
Pseudoephedrine—Agitation—Doxorubicin—uterine cancer	0.000692	0.00259	CcSEcCtD
Pseudoephedrine—Anxiety—Epirubicin—uterine cancer	0.000691	0.00259	CcSEcCtD
Pseudoephedrine—Vertigo—Doxorubicin—uterine cancer	0.000677	0.00254	CcSEcCtD
Pseudoephedrine—Confusional state—Epirubicin—uterine cancer	0.00067	0.00251	CcSEcCtD
Pseudoephedrine—Palpitations—Doxorubicin—uterine cancer	0.000666	0.00249	CcSEcCtD
Pseudoephedrine—Hypertension—Doxorubicin—uterine cancer	0.00065	0.00244	CcSEcCtD
Pseudoephedrine—Tachycardia—Epirubicin—uterine cancer	0.000648	0.00243	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Epirubicin—uterine cancer	0.000642	0.00241	CcSEcCtD
Pseudoephedrine—Chest pain—Doxorubicin—uterine cancer	0.000641	0.0024	CcSEcCtD
Pseudoephedrine—Anxiety—Doxorubicin—uterine cancer	0.000639	0.0024	CcSEcCtD
Pseudoephedrine—Anorexia—Epirubicin—uterine cancer	0.000633	0.00237	CcSEcCtD
Pseudoephedrine—Confusional state—Doxorubicin—uterine cancer	0.00062	0.00232	CcSEcCtD
Pseudoephedrine—Insomnia—Epirubicin—uterine cancer	0.000601	0.00225	CcSEcCtD
Pseudoephedrine—Tachycardia—Doxorubicin—uterine cancer	0.0006	0.00225	CcSEcCtD
Pseudoephedrine—Hyperhidrosis—Doxorubicin—uterine cancer	0.000594	0.00223	CcSEcCtD
Pseudoephedrine—Dyspnoea—Epirubicin—uterine cancer	0.000592	0.00222	CcSEcCtD
Pseudoephedrine—Anorexia—Doxorubicin—uterine cancer	0.000586	0.0022	CcSEcCtD
Pseudoephedrine—Dyspepsia—Epirubicin—uterine cancer	0.000585	0.00219	CcSEcCtD
Pseudoephedrine—Decreased appetite—Epirubicin—uterine cancer	0.000578	0.00216	CcSEcCtD
Pseudoephedrine—Pain—Epirubicin—uterine cancer	0.000568	0.00213	CcSEcCtD
Pseudoephedrine—Insomnia—Doxorubicin—uterine cancer	0.000556	0.00208	CcSEcCtD
Pseudoephedrine—Dyspnoea—Doxorubicin—uterine cancer	0.000548	0.00205	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Epirubicin—uterine cancer	0.000548	0.00205	CcSEcCtD
Pseudoephedrine—Dyspepsia—Doxorubicin—uterine cancer	0.000541	0.00203	CcSEcCtD
Pseudoephedrine—Decreased appetite—Doxorubicin—uterine cancer	0.000534	0.002	CcSEcCtD
Pseudoephedrine—Pain—Doxorubicin—uterine cancer	0.000526	0.00197	CcSEcCtD
Pseudoephedrine—Body temperature increased—Epirubicin—uterine cancer	0.000525	0.00197	CcSEcCtD
Pseudoephedrine—Feeling abnormal—Doxorubicin—uterine cancer	0.000507	0.0019	CcSEcCtD
Pseudoephedrine—Body temperature increased—Doxorubicin—uterine cancer	0.000486	0.00182	CcSEcCtD
Pseudoephedrine—Asthenia—Epirubicin—uterine cancer	0.000477	0.00179	CcSEcCtD
Pseudoephedrine—Asthenia—Doxorubicin—uterine cancer	0.000441	0.00165	CcSEcCtD
Pseudoephedrine—Dizziness—Epirubicin—uterine cancer	0.000439	0.00165	CcSEcCtD
Pseudoephedrine—Vomiting—Epirubicin—uterine cancer	0.000422	0.00158	CcSEcCtD
Pseudoephedrine—Rash—Epirubicin—uterine cancer	0.000419	0.00157	CcSEcCtD
Pseudoephedrine—Dermatitis—Epirubicin—uterine cancer	0.000419	0.00157	CcSEcCtD
Pseudoephedrine—Headache—Epirubicin—uterine cancer	0.000416	0.00156	CcSEcCtD
Pseudoephedrine—Dizziness—Doxorubicin—uterine cancer	0.000407	0.00152	CcSEcCtD
Pseudoephedrine—Nausea—Epirubicin—uterine cancer	0.000395	0.00148	CcSEcCtD
Pseudoephedrine—Vomiting—Doxorubicin—uterine cancer	0.000391	0.00146	CcSEcCtD
Pseudoephedrine—Rash—Doxorubicin—uterine cancer	0.000388	0.00145	CcSEcCtD
Pseudoephedrine—Dermatitis—Doxorubicin—uterine cancer	0.000387	0.00145	CcSEcCtD
Pseudoephedrine—Headache—Doxorubicin—uterine cancer	0.000385	0.00144	CcSEcCtD
Pseudoephedrine—Nausea—Doxorubicin—uterine cancer	0.000365	0.00137	CcSEcCtD
Pseudoephedrine—ADRA1A—Signaling Pathways—RNF43—uterine cancer	0.000117	0.000235	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—AKR1C1—uterine cancer	0.000117	0.000234	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	0.000117	0.000233	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—uterine cancer	0.000116	0.000233	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—CTNNB1—uterine cancer	0.000116	0.000232	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—POLD1—uterine cancer	0.000115	0.00023	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling by GPCR—PIK3CA—uterine cancer	0.000114	0.000228	CbGpPWpGaD
Pseudoephedrine—NFATC1—Immune System—HRAS—uterine cancer	0.000114	0.000228	CbGpPWpGaD
Pseudoephedrine—NFATC1—Disease—PIK3CA—uterine cancer	0.000114	0.000227	CbGpPWpGaD
Pseudoephedrine—IL2—Immune System—KRAS—uterine cancer	0.000113	0.000227	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—PTEN—uterine cancer	0.000113	0.000226	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR ligand binding—CCL2—uterine cancer	0.000112	0.000225	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—ERBB2—uterine cancer	0.000112	0.000224	CbGpPWpGaD
Pseudoephedrine—ADRA1A—G alpha (q) signalling events—PIK3CA—uterine cancer	0.000112	0.000224	CbGpPWpGaD
Pseudoephedrine—ADRB1—GPCR ligand binding—CXCL8—uterine cancer	0.00011	0.00022	CbGpPWpGaD
Pseudoephedrine—TNF—Developmental Biology—CTNNB1—uterine cancer	0.00011	0.000219	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—RNF43—uterine cancer	0.000109	0.000218	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—uterine cancer	0.000109	0.000218	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	0.000108	0.000217	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—EP300—uterine cancer	0.000108	0.000215	CbGpPWpGaD
Pseudoephedrine—ADRB2—GPCR ligand binding—CXCL8—uterine cancer	0.000107	0.000215	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—AKR1C1—uterine cancer	0.000107	0.000215	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—INHBA—uterine cancer	0.000107	0.000215	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—CXCL8—uterine cancer	0.000106	0.000212	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling by GPCR—HRAS—uterine cancer	0.000105	0.000211	CbGpPWpGaD
Pseudoephedrine—NFATC1—Disease—HRAS—uterine cancer	0.000105	0.00021	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR ligand binding—CCL2—uterine cancer	0.000104	0.000209	CbGpPWpGaD
Pseudoephedrine—MAOA—Neuronal System—HRAS—uterine cancer	0.000104	0.000209	CbGpPWpGaD
Pseudoephedrine—IL2—Immune System—PIK3CA—uterine cancer	0.000104	0.000208	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—CDKN1B—uterine cancer	0.000104	0.000207	CbGpPWpGaD
Pseudoephedrine—IL2—GPCR downstream signaling—AKT1—uterine cancer	0.000103	0.000205	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—VEGFA—uterine cancer	0.000102	0.000204	CbGpPWpGaD
Pseudoephedrine—TNF—Developmental Biology—EP300—uterine cancer	0.000102	0.000204	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—NRAS—uterine cancer	0.000101	0.000201	CbGpPWpGaD
Pseudoephedrine—NFATC1—Immune System—AKT1—uterine cancer	0.000101	0.000201	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—uterine cancer	0.0001	0.0002	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—INHBA—uterine cancer	9.97e-05	0.000199	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—CTNNB1—uterine cancer	9.79e-05	0.000196	CbGpPWpGaD
Pseudoephedrine—SLC6A3—Neuronal System—HRAS—uterine cancer	9.71e-05	0.000194	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—AKR1C1—uterine cancer	9.66e-05	0.000193	CbGpPWpGaD
Pseudoephedrine—TNF—Developmental Biology—VEGFA—uterine cancer	9.64e-05	0.000193	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—STK11—uterine cancer	9.64e-05	0.000193	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—CYP19A1—uterine cancer	9.64e-05	0.000193	CbGpPWpGaD
Pseudoephedrine—IL2—Immune System—HRAS—uterine cancer	9.63e-05	0.000193	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—RRM2—uterine cancer	9.57e-05	0.000191	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—PTEN—uterine cancer	9.54e-05	0.000191	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—STAR—uterine cancer	9.53e-05	0.000191	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—AKR1B1—uterine cancer	9.53e-05	0.000191	CbGpPWpGaD
Pseudoephedrine—TNF—Developmental Biology—NRAS—uterine cancer	9.52e-05	0.000191	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling by GPCR—AKT1—uterine cancer	9.31e-05	0.000186	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—DCN—uterine cancer	9.29e-05	0.000186	CbGpPWpGaD
Pseudoephedrine—NFATC1—Disease—AKT1—uterine cancer	9.28e-05	0.000186	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—uterine cancer	9.25e-05	0.000185	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—AKR1C3—uterine cancer	9.19e-05	0.000184	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—EP300—uterine cancer	9.1e-05	0.000182	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Platelet activation, signaling and aggregation—PIK3CA—uterine cancer	9.09e-05	0.000182	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—AKR1C3—uterine cancer	8.99e-05	0.00018	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—AKR1C1—uterine cancer	8.98e-05	0.00018	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—PGR—uterine cancer	8.96e-05	0.000179	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR ligand binding—CXCL8—uterine cancer	8.89e-05	0.000178	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—PGR—uterine cancer	8.76e-05	0.000175	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—CYP11A1—uterine cancer	8.75e-05	0.000175	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—KRAS—uterine cancer	8.66e-05	0.000173	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—VEGFA—uterine cancer	8.62e-05	0.000172	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—YWHAE—uterine cancer	8.55e-05	0.000171	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—NRAS—uterine cancer	8.51e-05	0.00017	CbGpPWpGaD
Pseudoephedrine—IL2—Immune System—AKT1—uterine cancer	8.51e-05	0.00017	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—YWHAE—uterine cancer	8.36e-05	0.000167	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—AKR1C3—uterine cancer	8.27e-05	0.000165	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR ligand binding—CXCL8—uterine cancer	8.26e-05	0.000165	CbGpPWpGaD
Pseudoephedrine—TNF—Developmental Biology—KRAS—uterine cancer	8.2e-05	0.000164	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—FBXW7—uterine cancer	8.19e-05	0.000164	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—FBXW7—uterine cancer	8.02e-05	0.00016	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—PIK3CA—uterine cancer	7.96e-05	0.000159	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—TP53—uterine cancer	7.7e-05	0.000154	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—POLD1—uterine cancer	7.48e-05	0.00015	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—AKR1C3—uterine cancer	7.44e-05	0.000149	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Platelet activation, signaling and aggregation—AKT1—uterine cancer	7.42e-05	0.000148	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—HRAS—uterine cancer	7.36e-05	0.000147	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—KRAS—uterine cancer	7.33e-05	0.000147	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PGR—uterine cancer	7.25e-05	0.000145	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—MTHFR—uterine cancer	7.24e-05	0.000145	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—STK11—uterine cancer	7.16e-05	0.000143	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—CCL2—uterine cancer	7.13e-05	0.000143	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—STK11—uterine cancer	7.01e-05	0.00014	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—AKR1C1—uterine cancer	7e-05	0.00014	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—CCL2—uterine cancer	6.97e-05	0.000139	CbGpPWpGaD
Pseudoephedrine—TNF—Developmental Biology—HRAS—uterine cancer	6.97e-05	0.000139	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—YWHAE—uterine cancer	6.91e-05	0.000138	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—AKR1C3—uterine cancer	6.91e-05	0.000138	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PGR—uterine cancer	6.73e-05	0.000135	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—PIK3CA—uterine cancer	6.73e-05	0.000135	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—SOCS3—uterine cancer	6.71e-05	0.000134	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—FBXW7—uterine cancer	6.63e-05	0.000133	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—SOCS3—uterine cancer	6.56e-05	0.000131	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—TP53—uterine cancer	6.51e-05	0.00013	CbGpPWpGaD
Pseudoephedrine—NFATC1—Signaling Pathways—AKT1—uterine cancer	6.5e-05	0.00013	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—STK11—uterine cancer	6.44e-05	0.000129	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—CYP19A1—uterine cancer	6.44e-05	0.000129	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—YWHAE—uterine cancer	6.42e-05	0.000129	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CDKN2B—uterine cancer	6.42e-05	0.000128	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—EP300—uterine cancer	6.33e-05	0.000127	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CDKN2B—uterine cancer	6.28e-05	0.000126	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—RRM2—uterine cancer	6.24e-05	0.000125	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—IGF1R—uterine cancer	6.23e-05	0.000125	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—HRAS—uterine cancer	6.23e-05	0.000125	CbGpPWpGaD
Pseudoephedrine—ADRB1—GPCR downstream signaling—CXCL8—uterine cancer	6.21e-05	0.000124	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—FBXW7—uterine cancer	6.16e-05	0.000123	CbGpPWpGaD
Pseudoephedrine—TNF—Developmental Biology—AKT1—uterine cancer	6.15e-05	0.000123	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—IGF1R—uterine cancer	6.1e-05	0.000122	CbGpPWpGaD
Pseudoephedrine—ADRB2—GPCR downstream signaling—CXCL8—uterine cancer	6.07e-05	0.000121	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—DCN—uterine cancer	6.05e-05	0.000121	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—VEGFA—uterine cancer	6e-05	0.00012	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—NRAS—uterine cancer	5.92e-05	0.000118	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—SMAD3—uterine cancer	5.86e-05	0.000117	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—STK11—uterine cancer	5.79e-05	0.000116	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—CCL2—uterine cancer	5.77e-05	0.000115	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—SMAD3—uterine cancer	5.73e-05	0.000115	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—CYP11A1—uterine cancer	5.7e-05	0.000114	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—CXCL8—uterine cancer	5.64e-05	0.000113	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—FGFR2—uterine cancer	5.59e-05	0.000112	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—CXCL8—uterine cancer	5.51e-05	0.00011	CbGpPWpGaD
Pseudoephedrine—IL2—Signaling Pathways—AKT1—uterine cancer	5.5e-05	0.00011	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—FGFR2—uterine cancer	5.47e-05	0.000109	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—SOCS3—uterine cancer	5.43e-05	0.000109	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—AKR1C3—uterine cancer	5.39e-05	0.000108	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—STK11—uterine cancer	5.38e-05	0.000108	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—CCL2—uterine cancer	5.36e-05	0.000107	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CDKN2B—uterine cancer	5.19e-05	0.000104	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—KRAS—uterine cancer	5.1e-05	0.000102	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—IGF1R—uterine cancer	5.04e-05	0.000101	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—SOCS3—uterine cancer	5.04e-05	0.000101	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR downstream signaling—CXCL8—uterine cancer	5.02e-05	0.0001	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—MTHFR—uterine cancer	4.84e-05	9.68e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CDKN2B—uterine cancer	4.83e-05	9.65e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—ESR1—uterine cancer	4.78e-05	9.57e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—SMAD3—uterine cancer	4.74e-05	9.49e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—IGF1R—uterine cancer	4.69e-05	9.38e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—PIK3CA—uterine cancer	4.68e-05	9.37e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—ESR1—uterine cancer	4.68e-05	9.36e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—CXCL8—uterine cancer	4.67e-05	9.33e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—CXCL8—uterine cancer	4.56e-05	9.12e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—TP53—uterine cancer	4.53e-05	9.06e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—FGFR2—uterine cancer	4.52e-05	9.05e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—NRAS—uterine cancer	4.52e-05	9.04e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—NRAS—uterine cancer	4.42e-05	8.85e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—SMAD3—uterine cancer	4.41e-05	8.82e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—HRAS—uterine cancer	4.33e-05	8.67e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—CXCL8—uterine cancer	4.24e-05	8.48e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CCL2—uterine cancer	4.21e-05	8.42e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—FGFR2—uterine cancer	4.2e-05	8.41e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—STK11—uterine cancer	4.2e-05	8.39e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—CYP19A1—uterine cancer	4.2e-05	8.39e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CCL2—uterine cancer	4.12e-05	8.24e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—PTEN—uterine cancer	4.03e-05	8.06e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—GPCR downstream signaling—PIK3CA—uterine cancer	3.94e-05	7.88e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—KRAS—uterine cancer	3.89e-05	7.78e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—ESR1—uterine cancer	3.87e-05	7.74e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—GPCR downstream signaling—PIK3CA—uterine cancer	3.85e-05	7.7e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—EP300—uterine cancer	3.84e-05	7.69e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Hemostasis—AKT1—uterine cancer	3.83e-05	7.65e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—KRAS—uterine cancer	3.81e-05	7.62e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—NRAS—uterine cancer	3.66e-05	7.32e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—ESR1—uterine cancer	3.6e-05	7.19e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—PIK3CA—uterine cancer	3.58e-05	7.15e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—ERBB2—uterine cancer	3.51e-05	7.02e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—PIK3CA—uterine cancer	3.5e-05	7e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—ERBB2—uterine cancer	3.43e-05	6.87e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CCL2—uterine cancer	3.41e-05	6.82e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—NRAS—uterine cancer	3.4e-05	6.8e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CXCL8—uterine cancer	3.33e-05	6.66e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—HRAS—uterine cancer	3.31e-05	6.62e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CXCL8—uterine cancer	3.26e-05	6.52e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CDKN1B—uterine cancer	3.25e-05	6.5e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—HRAS—uterine cancer	3.24e-05	6.47e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—GPCR downstream signaling—AKT1—uterine cancer	3.22e-05	6.43e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR downstream signaling—PIK3CA—uterine cancer	3.19e-05	6.37e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CDKN1B—uterine cancer	3.18e-05	6.36e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CCL2—uterine cancer	3.17e-05	6.33e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—MTHFR—uterine cancer	3.15e-05	6.31e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—KRAS—uterine cancer	3.15e-05	6.3e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—GPCR downstream signaling—AKT1—uterine cancer	3.15e-05	6.29e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—CTNNB1—uterine cancer	3.07e-05	6.14e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—CTNNB1—uterine cancer	3e-05	6.01e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—PTEN—uterine cancer	2.99e-05	5.99e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—PIK3CA—uterine cancer	2.96e-05	5.92e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—PTEN—uterine cancer	2.93e-05	5.86e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—KRAS—uterine cancer	2.93e-05	5.85e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling by GPCR—AKT1—uterine cancer	2.92e-05	5.84e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—PIK3CA—uterine cancer	2.89e-05	5.79e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling by GPCR—AKT1—uterine cancer	2.86e-05	5.72e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—EP300—uterine cancer	2.86e-05	5.71e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—PIK3CA—uterine cancer	2.84e-05	5.69e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—ERBB2—uterine cancer	2.84e-05	5.68e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—EP300—uterine cancer	2.79e-05	5.59e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—VEGFA—uterine cancer	2.7e-05	5.41e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CXCL8—uterine cancer	2.69e-05	5.39e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—PTEN—uterine cancer	2.69e-05	5.38e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—PIK3CA—uterine cancer	2.69e-05	5.38e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—HRAS—uterine cancer	2.68e-05	5.35e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—NRAS—uterine cancer	2.67e-05	5.34e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—VEGFA—uterine cancer	2.65e-05	5.29e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—ERBB2—uterine cancer	2.64e-05	5.28e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CDKN1B—uterine cancer	2.63e-05	5.26e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—NRAS—uterine cancer	2.61e-05	5.23e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—GPCR downstream signaling—AKT1—uterine cancer	2.6e-05	5.21e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—EP300—uterine cancer	2.57e-05	5.14e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CXCL8—uterine cancer	2.5e-05	5.01e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—HRAS—uterine cancer	2.49e-05	4.97e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—CTNNB1—uterine cancer	2.49e-05	4.97e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CDKN1B—uterine cancer	2.44e-05	4.89e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PTEN—uterine cancer	2.42e-05	4.85e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—GPCR downstream signaling—AKT1—uterine cancer	2.42e-05	4.84e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling by GPCR—AKT1—uterine cancer	2.36e-05	4.73e-05	CbGpPWpGaD
Pseudoephedrine—MAOA—Metabolism—AKT1—uterine cancer	2.32e-05	4.64e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—EP300—uterine cancer	2.31e-05	4.62e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—CTNNB1—uterine cancer	2.31e-05	4.62e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—KRAS—uterine cancer	2.3e-05	4.6e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PTEN—uterine cancer	2.25e-05	4.5e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—KRAS—uterine cancer	2.25e-05	4.5e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling by GPCR—AKT1—uterine cancer	2.2e-05	4.39e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—VEGFA—uterine cancer	2.19e-05	4.38e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—NRAS—uterine cancer	2.16e-05	4.32e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—EP300—uterine cancer	2.15e-05	4.29e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—PIK3CA—uterine cancer	2.11e-05	4.23e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—PIK3CA—uterine cancer	2.07e-05	4.13e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—TP53—uterine cancer	2.04e-05	4.09e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—VEGFA—uterine cancer	2.03e-05	4.07e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—NRAS—uterine cancer	2.01e-05	4.02e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—TP53—uterine cancer	2e-05	4e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—HRAS—uterine cancer	1.95e-05	3.91e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—HRAS—uterine cancer	1.91e-05	3.82e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—PIK3CA—uterine cancer	1.9e-05	3.8e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—KRAS—uterine cancer	1.86e-05	3.72e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PTEN—uterine cancer	1.75e-05	3.51e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—KRAS—uterine cancer	1.73e-05	3.46e-05	CbGpPWpGaD
Pseudoephedrine—ADRB1—Signaling Pathways—AKT1—uterine cancer	1.73e-05	3.45e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—PIK3CA—uterine cancer	1.71e-05	3.42e-05	CbGpPWpGaD
Pseudoephedrine—ADRB2—Signaling Pathways—AKT1—uterine cancer	1.69e-05	3.38e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—EP300—uterine cancer	1.67e-05	3.35e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—TP53—uterine cancer	1.65e-05	3.31e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—PIK3CA—uterine cancer	1.59e-05	3.18e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—HRAS—uterine cancer	1.58e-05	3.16e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Metabolism—AKT1—uterine cancer	1.55e-05	3.1e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—TP53—uterine cancer	1.54e-05	3.07e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—HRAS—uterine cancer	1.47e-05	2.94e-05	CbGpPWpGaD
Pseudoephedrine—ADRA1A—Signaling Pathways—AKT1—uterine cancer	1.4e-05	2.79e-05	CbGpPWpGaD
Pseudoephedrine—ADRA2A—Signaling Pathways—AKT1—uterine cancer	1.3e-05	2.59e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—PIK3CA—uterine cancer	1.24e-05	2.48e-05	CbGpPWpGaD
Pseudoephedrine—CYP2D6—Metabolism—AKT1—uterine cancer	1.01e-05	2.02e-05	CbGpPWpGaD
